Cyclosporine/Everolimus Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Cyclosporine may slow down how quickly your body processes everolimus. Both agents can affect your kidneys.

What might happen:

The amount of everolimus in your blood may increase and cause more side effects than expected, including problems with your kidneys and blood disorders that result in unwanted blood clots.

What you should do about this interaction:

Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. They are frequently used together in patients who have received an organ transplant and if instructed to use both of them, you should take your cyclosporine at the same time as your everolimus. Keep all of your laboratory appointments. Let your doctor know if you have any unusual bleeding or bruising, hallucinations, bizarre behavior, signs of a stroke, headaches, fever, a change in the amount of urine you produce, or unusual fatigue.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Zortress (everolimus) US prescribing information. Novartis Pharmaceuticals Corporation January 12, 2018.
  • 2.Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002 Jan;42(1):95-9.
  • 3.Budde K, Lehne G, Winkler M, Renders L, Lison A, Fritsche L, Soulillou JP, Fauchald P, Neumayer HH, Dantal J. Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients. J Clin Pharmacol 2005 Jul;45(7):781-91.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.